The predominance of M2-polarized macrophages in the stroma of low-hypoxic bladder tumors is associated with BCG immunotherapy failure by Lima, Luís et al.
1 
 
The predominance of M2-polarized macrophages in the stroma of 
low-hypoxic bladder tumors is associated with BCG immunotherapy 
failure  
 
Authors:  
Luís Lima, MSc 1,2,3,4, * and Daniela Oliveira, BSc 1,*, Ana Tavares, BSc 1,5, Teresina 
Amaro, MD 6, Ricardo Cruz, MD 7, Maria J Oliveira, PhD8,9,10, José A Ferreira, PhD1,11 and 
Lúcio Santos, MD, PhD 1,12,13 
1
 Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Porto, Portugal 
2 
ICBAS, Abel Salazar Biomedical Sciences Institute, University of Porto, Porto, Portugal 
3 
Núcleo de Investigação em Farmácia - Centro de Investigação em Saúde e Ambiente (CISA), School of 
Allied Health Sciences – Polytechnic Institute of Oporto, Porto, Portugal 
4 
LPCC, Research Department-Portuguese League Against Cancer (NRNorte), Portugal 
5 
Department of Pathology, Portuguese Institute of Oncology, Porto, Portugal
 
 
6
 Department of Anatomic Pathology, Hospital Pedro Hispano, Matosinhos, Portugal 
7 
Department of Urology, Portuguese Institute of Oncology, Porto, Portugal 
8 
INEB - Institute of Biomedical Engineering, Porto University 
9
Department of Pathology e Oncology, Faculty of Medicine, Porto University 
10 
Department of Biology, Faculty of Sciences, Porto University 
11
 QOPNA, Mass Spectrometry Center of the University of Aveiro, Campus de Santiago, Aveiro, Portugal 
12
 Health Faculty of University Fernando Pessoa, Porto, Portugal  
13 
Department of Surgical Oncology, Portuguese Institute of Oncology, Porto, Portugal 
* Both authors have equally contributed to the work 
  
 
Correspondence 
Luís Lima, BSc, MSc. 
Experimental Pathology and Therapeutics Group 
IPO-Porto Research Center (CI-IPOP) 
Portuguese Institute of Oncology, Porto 
Rua Dr. António Bernardino de Almeida 
4200-072 Porto, Portugal 
e-mail: luis14lima@gmail.com 
tel: +351225084000 (ext.5111) 
*Manuscript (include title page and abstract)
Click here to view linked References
2 
 
ABSTRACT 
Objective: Bacillus Calmette-Guerin (BCG) immunotherapy is the gold standard treatment for 
superficial intermediate/high risk of recurrence or progression bladder tumors. However, 
approximately 30% of patients fail to respond to treatment. Effective BCG therapy needs 
precise activation of the Th1 immune pathway. Tumor-associated macrophages (TAMs) often 
assume an immunoregulatory M2 phenotype and may directly interfere with the BCG induced 
antitumor immune response. Thus, we aim to clarify the influence of TAMs, in particular of the 
M2-phenotype in stroma and tumor areas, in BCG treatment outcome.  
Patients and methods: The study included 99 bladder cancer patients treated with BCG. 
Tumors resected prior to treatment were evaluated using immunohistochemistry for CD68 and 
CD163 antigens, which identify a lineage macrophage marker and a M2-polarized specific cell 
surface receptor, respectively.  CD68+ and CD163+ macrophages were evaluated within the 
stroma and tumor areas and high density of infiltrating cells spots were selected for counting. 
Hypoxia, an event known to modulate macrophage phenotype, was also accessed through HIF-
1α expression. 
Results: Patients in which BCG failed had high stroma-predominant CD163+ macrophage 
counts (high stroma but low tumor CD163+ macrophages counts) when compared with the 
ones with a successful treatment (71% vs. 47%; p=0.017). Furthermore, patients presenting 
this phenotype showed decreased recurrence-free survival (log rank, p=0.008) and a clear 2-
fold increased risk of BCG treatment failure was observed in univariate analysis (HR=2.343; 
95%CI: [1.197-4.587]; p=0,013). Even when adjusted to potential confounders, such as age and 
therapeutic scheme, multivariate analysis revealed 2.6-fold increased risk of recurrence 
(HR=2.627; 95%CI: [1.340-5.150]; p=0.005). High stroma-predominant CD163+ macrophage 
counts were also associated with low expression of HIF-1α in tumor areas, whereas high 
counts of CD163+ in the tumor, presented high expression of HIF-1α in tumor nests. 
 Conclusions: TAMs evaluation using CD163 is a good indicator of BCG treatment failure. 
Moreover, elevated infiltration of CD163+ macrophages predominantly in stroma areas but not 
in the tumor may be a useful indicator of BCG treatment outcome, possibly due to its 
immunosuppressive phenotype.  
 
 
Keywords: Bladder cancer, BCG immunotherapy, Tumor-associated macrophages, CD68, 
CD163 
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INTRODUCTION 
 Bladder cancer (BC) is the second most common urologic cancer and has the highest 
recurrence ratio of any malignancy [1]. Approximately 75-85% of all BC are non-muscle 
invasive (NMIBC), which includes carcinoma in situ (CIS) and papillary tumors confined to the 
mucosa or submucosa (Ta/T1) [1]. The NMIBC risk classification divides patients into low, 
intermediate and high-risk categories for recurrence and progression [1]. The gold standard 
treatment for intermediate/high risk patients is intravesical instillations with Bacillus Calmette-
Guérin (BCG) [1]. However, 30–50% of patients fail to respond, and 15% show progression to 
muscle-invasive disease. In these cases, radical cystectomy is the treatment to follow [2]. 
Intravesical instillations of BCG induce a massive local immune response that is characterized 
by the expression of cytokines in the bladder, as well as an influx of granulocytes and 
mononuclear cells (lymphocytes and macrophages) into the tumor areas [3, 4]. 
 Tumor biology, tumor progression and response to therapy are influence by the tumor 
microenvironment [5, 6]. These includes stromal cells, infiltrating leukocytes and blood vessels 
(depending on tumor size), all of which contribute to the so-called tumor stroma [6]. Tumor-
associated macrophages (TAMs) are a major component of the tumor stroma that contribute 
to tumor progression  in several types of cancer [6, 7].   
Macrophages are polarized in two distinct functional forms, M1 and M2 [6-8].  The 
classical or M1 macrophages activate type 1 helper cells (Th1) that have the capability to kill 
pathogens, produce IL-2, IL-12 and pro-inflammatory cytokines that promote responses like 
cytotoxic T-cell activation [8]. In contrast, alternatively-activated M2 macrophages express low 
levels of IL-12 and high levels of IL-4 and IL-10, promoting Th2 cytokines that inhibit Th1 
responses [7]. However, associated to the tumor, M2-polarized macrophages comprise 
multiple subtypes that may contribute to immunosupression, angiogenesis, cell invasion and 
metastasis,  depending on the microenvironment [5, 9]. Also, cytokines and chemokines 
released by the tumor may recruit and modulate monocyte differentiation into M2-
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macrophages lineages that may differ from those in the stroma [6, 7]. As such, a detailed 
evaluation of macrophage phenotypes in both the tumor and the stroma as well as their 
microenvironment is needed to fully understand how M2-macrophages influence tumor 
behavior and ultimately the response to treatment. 
 The studies presented so far indicate that higher TAM counts are associated with lower 
recurrence free survival and high risk of BCG treatment failure [10-12]. Nevertheless, these 
conclusions were based exclusively on CD68 expression, a macrophage lineage marker that 
does not allow the discrimination between M1 and M2 phenotypes therefore adding bias to 
these observations [13, 14]. Also, patients that respond to BCG commonly release large 
amounts of Th1 cytokines [15], whereas high levels of Th2 cytokines (i.e. IL-4 and IL-10) seem 
to be related with BCG failure [16]. These observations support the idea that effective BCG 
therapy requires precise activation of the Th1 immune pathway [17, 18]. However, TAMs 
assuming an immunoregulatory M2-phenotype release Th2 cytokines that may directly 
interfere with the BCG induced antitumor immune response [7, 16, 18]. Still, no direct 
evidences have been presented supporting the association between higher counts of M2-
polarized macrophages and the failure of BCG treatment.  
Furthermore, macrophages in different localizations may present different phenotypes 
induced by the microenvironment. For  example, oxygen shortage is known to promote an 
accumulation of angiogenic M2-macrophages in tumor hypoxic areas, where HIF-1α enhances 
the expression of VEGF and decreases the production of classical Th2 cytokines [19]. Despite 
these observations, the influence of hypoxia in the modulation of M2-polarized macrophage 
distribution in bladder tumors and stroma and its association with BCG treatment outcome 
also remains unevaluated.     
 In resume, a clarification about the expression pattern of M2-macrophages in 
intermediate and high-risk of recurrence bladder tumors and the influence of hypoxia is 
needed to disclose their true predictive value in the context of BCG response.  In this study we 
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devoted to this matter by evaluating the overall TAMs (CD68+) as well as the M2 phenotype, 
based on CD163 expression, in both stroma and tumor areas.  As outlined, we correlated our 
findings with HIF-1α expression to disclose the influence of hypoxia in M2-macrophage 
accumulation and treatment outcome.    
 
METHODS 
 
Cohort of Patients 
 In this study were included 99 formalin fixed paraffin embedded (FFPE) tissues from 
patients treated with transurethral resection of bladder tumor (TURBT) and then submitted to 
BCG immunotherapy in the Urology Department of Portuguese Institute of Oncology – Oporto 
(IPO-Porto), between 1998 and 2006. All patients received induction BCG therapy for 6 
consecutive weeks, starting 2-3 weeks after surgery (iBCG) and were then submitted to mBCG 
schedule (the one used in our institute is iBCG + maintenance protocol with 2-weekly 
instillations every 3 months during 2 years). The iBCG group includes patients treated before 
the European Association of Urology guidelines  recommending the mBCG scheme [20] and 
patients showing significant intolerance to long BCG treatment. 
 The average age of the patients was 68 years (range 41-85). The male:female ratio was 
84:15. The patients were followed every 3 months during the first year, every 6 months in the 
second year and every 12 months thereafter by cystoscopy and urine cytology. The median 
follow-up time was 68 months (range:10-163months). 
 Recurrence was defined as the appearance of a tumor after the beginning of the 
treatment, with at least one tumor-free cystoscopy and cytology in-between. BCG failure, as 
opposed BCG success, was defined as patients submitted to BCG treatment with tumor 
recurrence. Finally, recurrence-free survival (RFS) was defined as the period between the 
beginning of the treatment and either recurrence or the most recent tumour-free cystoscopy 
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and cytology. All procedures were performed after patient’s inforŵed consent and approved 
by the Ethics Committee of IPO-Porto.. All clinicopathological information was obtained from 
patients’ clinical records. All tuŵour saŵples were reǀised ďy an experienced pathologist, 
regarding 2004 WHO grading criteria. 
 
Immunohistochemistry  
TAMs immunohistochemistry was performed with CD68 antibody (Monoclonal Mouse Anti-
Human CD68; Clone PG-M1; DAKO) at a dilution of 1:100 in PBS, after 1h incubation at 37°C. 
M2 macrophages were accessed with the CD163 antibody (Monoclonal Mouse Anti-Human 
CD163; Clone 10D6; Novocastra-Leica) at a dilution of 1:100 in PBS, after overnight incubation 
at 37°C. Immunohistochemical detections were performed using HRP Detection System Kit 
according to ŵanufacturer’s instructions. Diaŵinoďenzidine ;Iŵpact Daď, Vector Labs) was 
used for color development. Hypoxic sites were evaluated using HIF-1α antiďody ;Monoclonal 
Mouse Anti-Human HIF-1α; Clone H1αϲϳ; AďcaŵͿ at a dilution of 1:50 in PB“, after oǀernight 
incubation at 37°C.  
 
Immunohischemistry Scoring 
 CD68+ and CD163+ macrophages, infiltrating the stroma and tumor areas were counted 
by two independent observers (LL, DO) and validated by an experienced pathologist (TA). Each 
specimen was screened at low magnification (100x) and the five areas with highest number of 
positively stained cells (hot-spot area) were selected. Photographs were taken, at a 400x 
magnification, with a real area of 0.035 mm2, and TAMs number was counted. The criteria 
used for macrophage specific counting were as follows: i) cells must present the shape of a 
macrophage or exhibit the macrophage characteristic staining pattern; ii) must present cell 
nucleus; and iii) be birefringent if the size is small;. Macrophages were evaluated in the tumor 
stroma, which included the papillary axis, lymphoid aggregates and stroma, and in tumor 
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islets. Macrophages counts were classified as low or high according to their distribution in 
percentiles. The expression of HIF-1α was determined based on percentage of positive cells 
and stratified in groups was as follows: Low (negative or 1-10% nuclear or cytoplasmic staining) 
and High (10-50% or >50% nuclear or cytoplasmic staining). 
 
Statistical Analysis 
Statistical data analysis was performed using the IBM Statistical Package for Social 
Sciences—SPSS for Windows (version 20.0). Chi-square analysis was used to compare 
categorical variables. Correlation between macrophage counts and clinical variables was 
performed using Spearman rho test. Kaplan-Meier survival curves were used to evaluate 
correlation between TAMs counts and RFS, log-rank statistical test was used for curves 
comparison. Multivariate Cox regression analysis was used to assess the effect of TAMs density 
on the time to recurrence in BCG-treated patients and to adjust for potential confounders.  
 
RESULTS 
Association of Clinical and clinical characteristics with BCG treatment outcome 
Approximately 42.4% of the patients presented recurrences, with the median 
recurrence time of 38.5 months (range: 10-122). The median follow-up time of the patients 
free of recurrence was 97 months (range: 13-163). 
Table 1 shows the clinicopathologic parameters and its association with treatment 
response and RFS. An association was found ďetween patients’ age and treatment response, 
since 69% of the patients presenting BCG failure were over 65 years when compared with 
43.9% in the BCG success group (p=0.013). Consequently, patients over 65 years presented 
almost a 3-fold increased risk of recurrence (HR=2.763; 95%CI: [1.431-5.336]; p=0.002). 
Similarly, patients treated with mBCG presented a 50% risk reduction of recurrence (HR=0.500; 
95%CI: [0.271-0.919]; p=0.026).  Approximately 70% of the patients successfully treated were 
8 
 
submitted to a mBCG scheme ( vs. 45% of the patients presenting treatment failure, p=0.021). 
Interestingly, no association was found between treatment outcome and other characteristics 
such as gender, tumour stage, number, grade or size, CIS presence and prior recurrence. 
 
Pattern of macrophage infiltration 
 We started by evaluating the localization of macrophages within tumor specimens. We 
observed the presence of CD68+ and CD163+ macrophages in both tumor stroma and in tumor 
islets. The tumor stroma included the papillary axis, lymphoid aggregates and stroma. The 
mean count of CD68+ macrophages was 33 within stroma and 13 within tumor while for 
CD163+ macrophages within stroma and tumor was, respectively, 24 and 7. The mean ratio of 
CD163+/CD68+ macrophages was 51.3% in the tumor and 24.6% in the associated stroma. A 
moderate to strong CD68+ macrophage stroma infiltration was observed in 46% of the tumors 
while only 4% of cases had none CD68+ macrophage staining in tumor nest. A high CD163+ 
macrophages stroma infiltration was observed in 15% tumors while only 8% of tumors 
presented no CD163 staining in tumor nests. 
 
Correlation between clinical characteristics and CD68+ and CD163+ macrophage counts 
The correlation between clinical variables and the macrophages counts are indicated in 
Table 2. Our results evidenced that CD68+ and CD163+ macrophages counts within stroma and 
tumor were correlated with higher stage, grade and tumor size (Table 2, p<0.05). Similarly, 
higher counts of CD68 and CD163 within tumor were observed in primary tumors (Table 2, 
p<0.05). Interestingly, higher CD163/CD68 ratios in tumor nests were associated with the CIS 
presence (Table 2, p <0.05). No correlations were found regarding gender, age and 
multifocality. 
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CD68+ and CD163+ macrophages and BCG treatment outcome 
 To evaluate the CD68+ and CD163+ macrophages infiltration within stroma and tumor 
areas in the context of BCG treatment outcome, counts were stratified based on percentiles 
(25th, 50th, 75th). The same strategy was applied for the CD163/CD68 ratio.  
Regarding CD68 expression, no association was found between the counts and 
treatment outcome. On the other hand we observed that only CD163+ stroma counts falling 
within the 25th percentile (>19 macrophages) presented a trend association with treatment 
outcome; CD163+ macrophage counts in the stroma were classified as low (LS) or high (HS) 
accordingly. Namely, a higher frequency of patients with BCG failure presented HS (above the 
25th percentile) for CD163+ macrophages (83%) when compared with ones where BCG was 
successful (74%); yet this association was not statistically significant.  
We also observed that the LS phenotype was always associated with low macrophage 
tumor counts (LT) (Fig. 1A). Furthermore, the CD163+ LS phenotype (associated with LT) 
presented BCG treatment response rates similar to the cases with HS and high tumor 
CD163+counts (HT; >75th percentile – Fig. 1B). Based on these observations, we decided to 
merge these two groups (LS/LT and HS/HT) and compare it with the cases presenting HS but LT 
CD163+ counts. Taking into consideration the low CD163+ counts presented by the tumors 
included in the LT phenotype (<10 macrophages) in comparison with the high stroma counts, 
the group was termed high stroma-predominant CD163+ macrophage group (HSP, Fig. 1C).  
This comparison highlighted that a higher percentage of patients presenting BCG 
failure had HSP when compared to the ones where the treatment was successful (69% vs. 46%; 
p=0.020; Sensivity: 54.4%; Specifity: 69.1%; Fig. 2). No association was found regarding 
CD163+/CD68+ ratio and BCG treatment outcome.  
 In order to estimate the influence of higher CD163+ macrophages counts in terms of 
RFS after BCG treatment, a Kaplan-Meier analysis was performed (Fig. 3). Differences were 
found in terms of RFS between patients with LS and HS counts of CD163+ macrophages (mean 
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RFS: 126 vs 92 months; log rank, p=0.052; Fig.3A). Moreover, patients with HSP CD163+ 
macrophages counts presented a different behavior in terms of RFS (log rank, p=0.008; Fig.3B) 
and a lower RFS (mean: 85 months) than all the others (mean:123 months).  
 Univariate Cox Regression analysis revealed that patients with tumors presenting 
CD163+ macrophages HS counts had an increased risk trend for recurrence after treatment, 
(HR=2.115; 95%CI: [0.972-4.603]; p=0.059). Moreover, patients with tumors classified as HSP 
showed a clear 2-fold increased risk of BCG treatment failure (HR=2.343 95%CI: [1.197-4.587] 
p=0,013).  
 To assess the individual effect of CD163+ macrophage infiltration in BCG treatment 
outcome, multivariate analysis was performed.  When adjusted to potential confounders, such 
as age and therapeutic scheme, patients with HS CD163+ and HSP CD163+ counts had more 
than a 2-fold increased risk of recurrence (respectively, HR=2.402 95%CI: [1.211-4.763] 
p=0.012 and HR=2.627 95%CI: [1.340-5.150] p=0.005; Table 3).  
 
CD163+ Macrophages and expression of HIF-1α  
The association between CD163+ macrophages counts within tumor and hypoxia was 
evaluated based on HIF-1α expression. The expression of HIF-1α is represented by a nuclear 
and cytoplasmic staining at the invasive front of the tumor. It was also observed that tumor 
areas with high density of CD163+ macrophages expressed high amounts of HIF-1α (Fig. 4A&B). 
On the other hand, tumor areas with low CD163+ macrophages counts, independently of the 
counts in the stroma,  presented lower expression of HIF-1α (Fig. 4C&D). In resume, while the 
HSP and LS (that also present LT counts) phenotypes were associated with tumors showing low 
degree of hypoxia, samples presenting the HS/HT phenotypes are associated with highly 
hypoxic tumors (p<0.001). However, the expression of HIF-1α was not associated with BCG 
treatment outcome.  
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Discussion 
 Although BCG immunotherapy is the primary treatment option for intermediate/high 
risk bladder tumors, the failure rate is over 30% [1]. Therefore the identification of biomarkers 
able to predict treatment failure and to provide an early identification of those patients better 
served by alternative therapies is crucial for the management of this disease [4]. There are 
some biomarkers emerging in the literature, but at the moment none could be set as reliable 
to translate into clinical practice [21, 22].  
 One of the biomarkers with consistent results was the presence of TAMs in bladder 
tumors prior to BCG treatment, although more studies are needed to validate its relevance 
[10-12, 21, 22]. On the other hand, the marker used was CD68, a lineage marker found in both 
M1 and M2 macrophages [7]. Several authors showed that in order to accurately determine 
TAMs influence in prognosis and treatment outcome, M2-specific markers, such as CD163, 
should be used [23-26]. To address this subject we investigated the influence of TAMs (CD68+) 
and also the M2-polarized macrophage phenotype (CD163+), in the context of BCG treatment 
outcome. Taking into consideration that the microenvironment plays a determinant role in the 
modulation of the macrophage lineages we evaluated independently the tumor and the 
stroma. 
 We started by seeking associations between the patient’s clinicopathological 
characteristics and the BCG treatment outcome and found that it was influenced by age and 
treatment scheme (iBCG, mBCG). Therefore, these variables were considered potential 
confounders and were taken into account in multivariate analysis models to assess the TAMs 
influence in BCG outcome. We also observed that CD68+ and CD163+ macrophages counts in 
both the stroma and tumor were correlated with higher stage, grade and tumor size. Similar 
results were observed by other authors for bladder cancer using CD68 [12, 27]. The CD163+ 
macrophages identification has also been associated with poor prognosis in several types of 
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cancer [23, 28]; however this is the first study suggesting that the M2-subtype may be a 
characteristic of high-risk of recurrence/progression bladder tumors.   
Three studies have been presented supporting the idea that a higher density of 
macrophages in the tumor and its surroundings may be associated with BCG treatment failure 
[10-12]. However, we observed no associations between CD68+ macrophage counts in stroma 
and in tumor nests and the outcome. Even though contradictory these results may stem from 
the fact that two of this studies were conducted in a low number of samples (27 and 46) and 
did not take into consideration the localization of the macrophages. A third study involving a 
localization-based analysis in CIS, described that cases with a low density of tumor CD68+ 
macrophages presented higher recurrence-free rate. However the reduced number of CIS in 
our series does not allow an accurate comparison. Nevertheless, whether macrophage density 
influences treatment outcome in different ways depending on the histology of the tumor 
warrants a deeper evaluation.    
Contrastingly, we observed that a high density of M2-polarized macrophage counts in 
the stroma but not in the tumor related with BCG treatment failure.  Interestingly, cases 
presenting a high density of macrophages in the tumor presented a more favourable outcome. 
Furthermore, these cases behaved similarly to those presenting an overall low density of M2 
macrophages (LT/LS). These results suggest that M2-macrophages may be influencing 
treatment outcome in different ways possibly due to the influence of differentiated micro 
environmental stimuli in the stroma and the tumor.  
 Since TAMs may be found in vascularised stroma but also significantly accumulate in 
hypoxic areas within the tumor [19, 29, 30], we hypothesized that differences in CD163 
expression between tumor areas could be the result of hypoxia. This was confirmed by the 
association between high tumor CD163+ macrophage counts and high expression of the 
hypoxia marker HIF-1α within tuŵor areas; conǀersely, in speciŵens with High stroma-
predominant CD163+ counts (and respectively low tumor counts), HIF-1expression within 
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tumor areas was low. These observations suggest that hypoxic conditions may dictate the 
accumulation of CD163+ macrophages in bladder tumor areas.  
Hypoxia not only seems to dictate the accumulation of macrophages in the tumor but 
may also modulate the M2-macrophage phenotype. In particular, hypoxia is known to enhance 
the expression of angiogenic factors, producing high amounts of VEGF and other 
proinflammatory cytokines like TNF-α, IL-1β, MIF and COX2 that act as proŵoters of a Th1 
mediated response known to favour BCG action [19]. On the other hand, normoxia may favour 
the M2 immunosuppressive phenotype and the downregulation of molecules implicated in 
immunological activation such as IL-12, IL-18, IL-1β and TNFα [5]. This selective pressure also 
upregulates the expression of Th2-type cytokines, as well as IL-10, IL-1RA and TGF-β, soŵe of 
which have been associated with a lack of response to BCG treatment [16]. Based on these 
observations we hypothesize that hypoxic conditions may favour the accumulation of M2-
polarized macrophages in the tumor and also promote their angiogenic phenotype, ultimately 
leading to a better treatment outcome. Conversely, non-hypoxic or low-hypoxic conditions 
(low HIF-1αͿ decrease the density of macrophages in the tumor area, maintaining them in the 
stroma area. We may hypothesize that these macrophages present the immunosupressive 
phenotype, which in part may explain the higher treatment failure.  
Although our results point out that high stroma-predominant CD163+ macrophage 
counts is a good predictor of recurrence after BCG treatment, some limitations need to be 
overcome in order to use this biomarker in clinical practice. Namely, efforts should be taken to 
make the macrophage counts reproductive. It would be important to evaluate different 
counting methodologies, specially involving image acquisition and automatic counting 
software in order to create a standard technique and cut-off values. Also, this a preliminary 
study with 99 patients that requires validation in larger series and different cohorts. A careful 
evaluation of the influence of hypoxia and other microenvironment factors in the modulation 
of macrophage phenotypes is also needed in this context.  
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 Altogether, our results indicate that discrimination of M2 macrophages (CD163+) is a 
better indicator of treatment failure than the overall macrophage counting given by CD68. 
Moreover, our observations suggest that only M2 macrophages under normoxic conditions 
may exert an inhibitory effect on BCG immunotherapy, possibly due to its immunosuppressive 
phenotype.  
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Figure 1. Immunohistochemical staining showing different grades of CD163
+
 macrophages 
infiltration in bladder tumors (400x). Representative images (A-C) of macrophages stained 
with anti-CD163 (brown). A- Low Stroma and Low Tumor Macrophages infiltration (LS/LT); B- 
High Stroma and High Tumor Macrophages infiltration (HS/HT); C- High Stroma and Low Tumor 
Macrophages infiltration (HS/LT) – High Stroma-predominant Macrophages Counts. 
 
Figure 2. Association between combined CD163
+
 macrophages counts and BCG treatment 
failure. Higher stroma-restricted CD163+ macrophages counts were associated with non-
response after BCG immunotherapy. LS/LT: Low Stromal and Low tumor; HS/HT: High Stromal 
and High Tumor; HS/LT: High Stromal and Low Tumor – High Stroma-predominant Counts. ͞*͟ 
p=0.020 (Chi-square Test).  
 
Figure 3. Effect M2-polarized TAMs in recurrence-free survival (RFS). Kaplan-Meier analysis to 
evaluate the association between RFS in the studied patients and: A- CD163+ macrophages 
counts in stroma; B- CD163+ macrophages combined counts. High Stroma-predominant counts 
(HS/LT: High Stromal but Low Tumor Counts) vs. LS/LT (Low Stromal and Low Tumor counts) or 
HT/HT (High Stromal with High Tumor counts). Comparison performed by log-rank test (A: 
p=0.052; B: p=0.008Ϳ; + censored ͞Low Counts͟ or ͞L“/LT  or H“/HT͟ cases; ♦ censored ͞High 
Counts͟ or ͞High Stroma-predominant Counts ;H“/LTͿ͟ cases.  
 
Figure 4. Immunohistochemical staining showing different grades of CD163+ macrophages 
infiltration and HIF-1α in the tumor nest of bladder cancer (100x). Representative images (A 
and C) of Macrophages stained with anti-CD163 (brown) and the same areas stained with anti-
HIF-1α (brown - B and D). A- High infiltration of CD163+ Macrophages in tumor; B- High 
staining of HIF-1 α in tumor; C- Low infiltration of CD163+ Macrophages in tumor; D- Low 
staining of HIF-1 α in tumor; 
 
 
Figure legends
Table 1. Relation between patients clinical and tumour characteristics and response 
to BCG treatment and time to recurrence. 
Variables Total Responders Non-
Responders 
HR [95% CI] p* 
 n (%) n (%) n (%)   
Age      
<65 years 45 (45,5) 32 (56,1) 13 (31,0) 1.0  
≥ϲϱ years 54 (54,5) 25 (43,9) 29 (69,0) 2,763 [1,431-5,336] 0,002 
Sex      
Male 84 (84,8) 46 (80,7) 38 (90,5) 1.0  
Female 15 (15,2) 11 (19,3) 4 (9,5) 0,526 [0,187-1,478] 0,223 
Stage      
Ta 40 (40,4) 22 (38,6) 18 (42,9) 1.0  
T1 59 (59,6) 35 (61,4) 24 (57,1) 0,961 [0,521-1,773] 0,899 
Grade      
Low 39 (39,4) 24 (42,1) 15 (35,7) 1.0  
High 60 (60,6) 33 (57,9) 27 (64,3) 1,410 [0,749-2,654] 0,287 
Size (cm)      
<3 64 (65,3) 36 (63,2) 28 (68,3) 1.0  
≥3 34 (34,7) 21 (36,8) 13 (31,7) 0,760 [0,393-1,470] 0,416 
Tumor number      
Unifocal 45 (45,5) 29 (50,9) 16 (38,1) 1.0  
Multifocal 54 (54,5) 28 (49,1) 26 (61,9) 1,729 [0,924-3,235] 0,087 
CIS      
No 92 (92,9) 53 (93,0) 39 (92,9) 1.0  
Yes 7 (7,1) 4 (7,0) 3 (7,1) 0,944 [0,291-3,056] 0,923 
Recurrence Status      
Primary 51 (51,5) 33 (57,9) 18 (42,9) 1.0  
    Recurrent 48 (48,5) 24 (42,1) 24 (57,1) 1,562 [0,847-2,881] 0,153 
BCG schedule      
iBCG 41 (41,4) 18 (31,6) 23 (54,8) 1.0  
mBCG 58 (58,6) 39 (68,4) 19 (45,2) 2,002 [1,088-3,684] 0,026 
 
HR: Hazard Ratio; CI: Confidence Interval; CIS: Carcinoma in situ. 
* 
: Wald test 
 
Table 1
 Table 2. Correlation between clinical parameters and CD68+ and CD163+ macrophages 
counts, in tumor stroma and tumor nest. 
 
 
CIS: Carcinoma in situ. 
P value
 
: Chi-square test 
 
 
 
CD68
+
 macrophages counts CD163
+
 macrophages counts CD163
+
/CD68
+
 macrophage ratio 
Tumor Stroma Tumor Nest Tumor Stroma Tumor Nest Tumor Stroma Tumor Nest 
Correlation 
coefficient 
P value 
Correlation 
Coefficient 
P value 
Correlation 
Coefficient 
P value 
Correlation 
Coefficient 
P value 
Correlation 
Coefficient 
P value 
Correlation 
Coefficient 
P value 
Age 0,026 0,802 -0,030 0,770 0,012 0,906 0,034 0,735 -0,015 0,884 0,014 0,897 
Sex -0,046 0,649 0,129 0,204 -0,066 0,519 0,166 0,101 -0,028 0,786 0,074 0,477 
Stage 0,371 0,000 0,271 0,007 0,274 0,006 0,300 0,003 0,116 0,253 -0,012 0,907 
Grade 0,284 0,004 0,194 0,054 0,232 0,021 0,278 0,005 0,135 0,184 0,126 0,223 
Size 0,263 0,009 0,290 0,004 0,172 0,090 0,284 0,005 0,220 0,029 0,109 0,294 
Tumor 
Number 
-0,081 0,424 -0,023 0,818 0,004 0,972 0,012 0,903 -0,062 0,544 0,093 0,369 
CIS -0,176 0,082 0,072 0,481 -0,137 0,178 0,046 0,655 0,105 0,302 0,280 0,006 
Primary / 
Recurrent 
-0,120 0,239 -0,273 0,006 -0,037 0,718 -0,229 0,023 0,023 0,824 0,020 0,850 
Table 2
Table 2. Multivariate analysis and risk estimation of CD163+ macrophages influence on 
BCG therapy outcome. 
LS/LT: Low Stromal and Low tumor counts;  
HS/HT: High Stromal and High Tumor counts ;  
HS/LT: High Stromal but Low Tumor counts; 
HR: Hazard Ratio; CI: Confidence Interval 
a
 adjusted for age and BCG schedule 
 
 
 
 
 
 
CD163
+
 macrophages HR
a 
95%CI p value 
Stromal Counts    
Low (≤19)  1.0 Referent  
High (>19)  2,402
 
1.211-4.763 0.012 
    
Combined Counts    
LS/LT or HS/HT 1.0 Referent  
High Stroma-predominant Counts (HS/LT)  2.627 1.340-5.150 0.005 
Table 3
